We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
Cap. Flow
+$71.5M
Cap. Flow %
2.43%
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$85.5M
2
QURE icon
uniQure
QURE
+$52M
3
LH icon
Labcorp
LH
+$50.7M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$46.9M
5
IFRX icon
InflaRx
IFRX
+$40.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$78.7M
2
PBYI icon
Puma Biotechnology
PBYI
+$74.6M
3
PEN icon
Penumbra
PEN
+$67.6M
4
ABT icon
Abbott
ABT
+$39.2M
5
RGNX icon
Regenxbio
RGNX
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.2%
2 Miscellaneous 1.77%
3 Financials 1.03%
4 Technology 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$39.7M 1.35%
2,957,765
+2,200
+0.1% +$27.5K
MOR
27
DELISTED
MorphoSys AG American Depositary Shares
MOR
$38.5M 1.31%
+1,269,800
New +$34.9M
ANAB icon
28
AnaptysBio
ANAB
$1.67B
$36.9M 1.25%
519,250
-3,900
-0.7% -$327K
HSKA
29
DELISTED
Heska Corp
HSKA
$36.8M 1.25%
354,776
+116,330
+49% +$10.9M
UNH icon
30
UnitedHealth
UNH
$353B
$35.1M 1.19%
143,020
-2,400
-2% -$576K
ELV icon
31
Elevance Health
ELV
$85.5B
$34.8M 1.18%
+146,000
New +$33.8M
CBIO
32
Crescent Biopharma
CBIO
$659M
$32.7M 1.11%
20,293
-2,530
-11% -$4.35M
IRTC icon
33
iRhythm Holdings
IRTC
$3.96B
$32.6M 1.11%
401,303
-328,571
-45% -$23M
EHTH icon
34
eHealth
EHTH
$38.4M
$30.5M 1.03%
1,377,895
+47,400
+4% +$914K
OXFD
35
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$28.8M 0.98%
2,235,207
-234,480
-9% -$3.17M
NITE
36
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$28.6M 0.97%
1,785,446
+16,500
+0.9% +$235K
CTLT
37
DELISTED
CATALENT, INC.
CTLT
$27.7M 0.94%
+661,850
New +$26.7M
ABT icon
38
Abbott
ABT
$195B
$27.4M 0.93%
449,300
-646,800
-59% -$39.2M
EPZM
39
DELISTED
Epizyme, Inc
EPZM
$27.4M 0.93%
2,021,389
+9,400
+0.5% +$146K
SRRK icon
40
Scholar Rock
SRRK
$7.04B
$27.3M 0.93%
+1,750,408
New +$32.8M
ELGX
41
DELISTED
Endologix Inc
ELGX
$24.5M 0.83%
432,639
-159,677
-27% -$8.1M
TFX icon
42
Teleflex
TFX
$5.92B
$21.4M 0.73%
79,886
-96,700
-55% -$25.9M
ZTS icon
43
Zoetis
ZTS
$32B
$21.2M 0.72%
+249,100
New +$21M
CMRX
44
DELISTED
Chimerix, Inc.
CMRX
$17.1M 0.58%
3,589,490
-139,200
-4% -$665K
SYRS
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$16.7M 0.57%
163,124
-2,100
-1% -$260K
TCDA
46
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.9M 0.51%
+500,000
New +$14M
ODT
47
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$13.5M 0.46%
610,600
+16,400
+3% +$382K
TDOC icon
48
Teladoc Health
TDOC
$1.18B
$13.4M 0.46%
231,000
-42,200
-15% -$2.06M
PEN icon
49
Penumbra
PEN
$12.7B
$9.97M 0.34%
72,170
-474,909
-87% -$67.6M
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.3M 0.32%
1,214,593
+32,200
+3% +$464K
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2018 Portfolio in Review

As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
  • Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
  • Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
  • Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
  • Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
  • Redmile Group opened 27 new positions and closed 12 in Q2 2018.
  • Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.